US Patent 9,216,178: Claim Scope, Expiration, Orange Book Position, and Sapropterin Patent Landscape

US Patent 9,216,178 protects a specific dry-blend formulation of sapropterin dihydrochloride, the active ingredient in BioMarin’s Kuvan product. The patent is formulation-specific rather than a basic compound patent. Its core requirement is a powder containing approximately 32% sapropterin dihydrochloride, 54% mannitol, 1.9% sucralose, 10.4% potassium citrate, and 1.6% ascorbic acid, combined with a three-month stability result at 40°C and 75% relative humidity.

The claims also cover compositions containing approximately 100 mg or 500 mg of sapropterin dihydrochloride. Those amounts correspond closely to the commercial Kuvan powder-packet strengths. The principal commercial risk is therefore substitution with a generic powder that uses the same or materially equivalent excipient system.

What does US Patent 9,216,178 protect?

The patent protects a pharmaceutical composition in dry-blend powder form. Claim 1 has two independent categories of limitations:

A defined quantitative formulation.
A defined stability result under accelerated storage conditions.

The claimed active ingredient is "(6R)-L-erythro-tetrahydrobiopterin dihydrochloride," also known as sapropterin dihydrochloride.

Component	Claimed approximate percentage by weight
Sapropterin dihydrochloride	32%
Mannitol	54%
Sucralose	1.9%
Potassium citrate	10.4%
Ascorbic acid	1.6%
Total	99.9%, reflecting rounding

The formulation must also retain at least 90% of the initial amount of sapropterin after three months at 40°C and 75% relative humidity. The stability limitation is material. A powder with the same nominal excipient percentages but without the required stability performance would present a different infringement analysis from a powder that satisfies the stability limitation.

How should the claims be construed?

Claim 1 requires the complete formulation

Claim 1 is not directed broadly to any stable sapropterin composition. It identifies five formulation components and assigns an approximate concentration to each. A competing composition that omits mannitol, substitutes a different sweetener for sucralose, or materially changes the citrate or ascorbic-acid content may avoid literal infringement.

The term "about" creates numerical tolerance, but it does not eliminate the quantitative character of the claim. The relevant range would normally depend on the patent specification, prosecution history, technical meaning of the percentages, and how a court interprets the term in context. The claim does not state an express tolerance such as plus or minus 5%.

The stability test is a separate limitation

The claimed composition must retain at least 90% of the initial sapropterin under the specified accelerated condition:

Temperature: 40°C
Relative humidity: 75%
Duration: three months
Retention threshold: at least 90%

The claim does not merely require that the formulation be designed for stability. It recites a performance result. Analytical methodology, assay variability, sampling procedures, degradation-product measurements, and the meaning of "initial amount" may become central in litigation.

Claims 2 through 4 narrow the active dose

Claim 2 covers an initial sapropterin amount from approximately 100 mg to approximately 500 mg. Claims 3 and 4 separately identify approximately 100 mg and approximately 500 mg.

Claims 3 and 4 are composition claims, not method-of-treatment claims. They do not require administration to a patient, a particular disease, a dosing schedule, or a clinical outcome.

What are the theoretical powder quantities for the 100 mg and 500 mg embodiments?

Assuming the 32% active-ingredient percentage is applied directly, the approximate batch quantities are as follows.

Parameter	100 mg embodiment	500 mg embodiment
Total powder mass at 32% active	312.5 mg	1,562.5 mg
Sapropterin dihydrochloride	100 mg	500 mg
Mannitol at 54%	168.75 mg	843.75 mg
Sucralose at 1.9%	5.94 mg	29.69 mg
Potassium citrate at 10.4%	32.5 mg	162.5 mg
Ascorbic acid at 1.6%	5 mg	25 mg

The calculation assumes that the stated percentages are weight percentages of the finished dry blend and that the active amount is measured on the same basis used in the patent. Commercial manufacturing may use a different accounting convention if moisture, hydrate content, potency correction, or salt-form equivalence is handled separately.

When does US Patent 9,216,178 expire?

The patent issued on December 22, 2015. Its enforceable term is governed by the 20-year patent-term rule measured from the applicable US nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, and any other term modifications recorded in the USPTO file history.[1]

Public patent records commonly associate the patent family with a December 2007 priority date. Priority date alone does not establish the expiration date. The controlling date is the applicable nonprovisional filing date, together with any patent-term adjustment and terminal disclaimer information.

A definitive expiration analysis should distinguish:

Date category	Legal significance
Earliest priority date	Establishes priority relationship and prior-art position
US nonprovisional filing date	Usually controls the 20-year patent term
Patent issue date	Does not ordinarily determine expiration
Patent-term adjustment	Can extend the calculated term
Terminal disclaimer	Can shorten the term to align with another patent
Patent expiration date	Determines when ordinary patent enforcement ends

The patent’s expiration should therefore be confirmed against the current USPTO Patent Center record and the FDA Orange Book patent listing before relying on a specific launch date.[1][2]

What is the Orange Book status of US Patent 9,216,178?

US Patent 9,216,178 is associated with the sapropterin dihydrochloride product Kuvan, which FDA approved for phenylketonuria.[2][3] The patent is relevant to the powder dosage form, particularly the 100 mg and 500 mg powder presentations.

The Orange Book analysis should separate three issues:

Whether the patent is listed against a specific approved drug product.
Which dosage forms and strengths are covered by the listing.
Whether the listed patent remains unexpired and enforceable on the relevant date.

An Orange Book listing does not prove that every sapropterin product infringes. It identifies a patent that the NDA holder represents as claiming the drug, a method of using the drug, or an approved formulation. In this case, the claim language is directed to a formulation and does not expressly require a method of treatment.

The approved Kuvan product has included 100 mg and 500 mg oral powder packets. FDA labeling identifies sapropterin dihydrochloride as the active ingredient and describes administration after mixing the powder with a beverage or soft food.[3]

Does the patent cover Kuvan tablets?

The supplied claims are directed to a dry-blend powder. They do not expressly cover a tablet, capsule, liquid solution, or other dosage form.

A tablet could fall within the claims only if it is legally characterized as the claimed dry-blend powder composition before compression or otherwise satisfies every claim limitation. The finished dosage form alone does not determine infringement. The relevant questions include:

Whether the tablet contains the claimed ingredients.
Whether the ingredients are present in the claimed approximate percentages.
Whether the powder composition satisfies the stability requirement.
Whether the formulation is the claimed dry blend or a materially different dosage-form composition.

The patent presents a stronger direct read on powder packets than on tablets.

What generic entry risks exist for sapropterin products?

A generic applicant seeking approval for a product that relies on Kuvan may need to address listed patents through one of the FDA’s statutory certifications. A Paragraph IV certification would assert that the listed patent is invalid, unenforceable, or not infringed. FDA approval can trigger patent litigation under Hatch-Waxman if the NDA holder or patent owner files suit within the statutory period.[4]

For this patent, a generic applicant could develop several design-around strategies:

Strategy	Potential effect
Change one or more excipients	May avoid literal composition overlap
Use a different sweetener	Could avoid the sucralose limitation
Use a different buffer system	Could avoid the potassium-citrate limitation
Alter the antioxidant system	Could avoid the ascorbic-acid limitation
Use a tablet or capsule	May reduce direct exposure to a powder claim
Use a different active concentration	May avoid the 100 mg or 500 mg limitations, but not necessarily claim 1
Use a formulation that fails the claimed stability result	May avoid literal infringement, subject to regulatory and commercial consequences

The stability limitation creates a potential noninfringement position, but deliberately using an unstable formulation would generally be commercially impractical. A generic manufacturer must meet FDA quality, shelf-life, and product-performance requirements even if the selected composition is outside the patent claim.

How strong is the patent estate for sapropterin?

The commercial strength of US Patent 9,216,178 is narrower than that of a compound patent. Sapropterin dihydrochloride is an established active ingredient, and the patent does not claim the molecule itself. Its value lies in the formulation architecture and the apparent alignment between the claimed 100 mg and 500 mg powder amounts and the marketed powder presentations.

Strengths

Directly targets a commercial powder formulation.
Covers the two principal powder strengths recited in the claims.
Includes a measurable stability requirement.
Can create regulatory litigation risk for an ANDA applicant if listed in the Orange Book.
May be difficult to design around while preserving taste, stability, manufacturability, and shelf life.

Limitations

The claims require a specific excipient combination.
The claims do not broadly cover every sapropterin dosage form.
The claims do not cover sapropterin as a chemical entity.
The stability limitation may require extensive analytical evidence.
The term "about" may create claim-construction disputes.
A substantially different powder system may avoid literal infringement.

The patent is therefore best characterized as a focused formulation barrier rather than a broad platform patent.

What manufacturing and intellectual-property barriers remain after patent expiry?

After expiration, ordinary patent enforcement based on this patent should end, but other barriers may remain. These can include:

FDA approval requirements for the generic product.
Bioequivalence or pharmaceutical-equivalence requirements.
Control of sapropterin active pharmaceutical ingredient supply.
Manufacturing know-how for blending, moisture control, and packaging.
Stability data supporting the proposed shelf life.
Trade secrets involving particle size, blending order, and packaging materials.
Separate patents covering other formulations, uses, dosage forms, or manufacturing processes.
Regulatory exclusivity or pediatric-exclusivity periods, if applicable.

Patent expiry therefore does not guarantee immediate commercial launch. It removes one legal barrier while leaving regulatory, supply-chain, and manufacturing requirements in place.

Which companies are challenging the sapropterin patent?

The supplied patent claims do not identify an ANDA applicant, Paragraph IV challenger, settlement agreement, or active patent litigation. Patent ownership, FDA listing, and litigation participation are separate records. A complete competitor analysis must therefore be based on current USPTO, FDA, and federal-court records rather than inferred from the claim language.

No Paragraph IV challenger or settlement party should be attributed to US Patent 9,216,178 without a current statutory notice, FDA listing, or court docket confirming that position.

What revenue exposure does the patent create?

The patent’s revenue exposure is concentrated in sapropterin powder products rather than the entire tetrahydrobiopterin market. A generic entrant that launches a powder with the same active dose and a materially similar excipient system could compete directly with the protected commercial presentation.

The key commercial variables are:

Share of sapropterin sales generated by powder packets.
Relative sales of 100 mg and 500 mg packets.
Availability of tablet or alternative formulations.
Number and timing of ANDA applicants.
Patent-term expiration and any applicable regulatory exclusivity.
Ability of a generic applicant to use a non-infringing formulation.
Physician and payer willingness to substitute.

The patent is most valuable while the 100 mg and 500 mg powder products remain commercially important and while competing formulations cannot meet FDA requirements without using a similar stability system.

How does US Patent 9,216,178 compare with a compound patent?

Issue	US 9,216,178	Compound patent
Protected subject matter	Dry-blend formulation	Chemical entity or salt
Breadth	Narrow to listed ingredients and performance	Usually broader against products containing the molecule
Product exposure	Primarily powder formulations	Potentially all products containing the compound
Design-around potential	Relatively higher	Usually lower before expiry
Stability testing relevance	Central to claim 1	Often secondary
Generic litigation risk	Depends heavily on formulation design	Usually applies to nearly every equivalent product
Commercial value	Concentrated in a dosage form	Extends across formulations and indications

Key Takeaways

US Patent 9,216,178 is a formulation patent for dry-blend sapropterin dihydrochloride powder.
Claim 1 requires approximately 32% sapropterin, 54% mannitol, 1.9% sucralose, 10.4% potassium citrate, and 1.6% ascorbic acid.
The composition must retain at least 90% of its initial sapropterin after three months at 40°C and 75% relative humidity.
Claims 2 through 4 cover approximately 100 mg, 500 mg, and the intervening 100 mg-to-500 mg dose range.
The patent is more directly relevant to Kuvan powder packets than to tablets or unrelated sapropterin dosage forms.
The patent does not claim sapropterin as a chemical entity.
Generic applicants may pursue formulation design-arounds or challenge the patent through a Paragraph IV certification.
A specific expiration date should be taken from the current USPTO term record, including patent-term adjustment and any terminal disclaimer.
Patent scope alone does not establish the identity of a current Paragraph IV challenger or settlement participant.

FAQs

Does US Patent 9,216,178 cover all sapropterin products?

No. The claims are limited to a specified dry-blend formulation and related dose amounts. They do not broadly cover every sapropterin product.

Can a generic avoid the patent by replacing sucralose?

Potentially. Replacing sucralose may avoid literal infringement if the resulting product does not satisfy the complete claim. The remaining formulation, stability result, and doctrine-of-equivalents analysis would still matter.

Is the 90% stability requirement optional?

No. It is an express limitation of claim 1. A composition that does not satisfy the stated stability result would not literally meet claim 1.

Does the patent cover a 100 mg sapropterin tablet?

Not automatically. Claim 3 recites approximately 100 mg, but the product must also satisfy claim 1’s dry-blend formulation, ingredient percentages, and stability requirement.

Does patent expiry eliminate FDA approval requirements for generic sapropterin?

No. FDA approval, pharmaceutical equivalence, bioequivalence, manufacturing controls, and stability requirements continue after patent expiration.

References

United States Patent and Trademark Office. (2015). US Patent No. 9,216,178, pharmaceutical composition comprising tetrahydrobiopterin.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (n.d.). Kuvan (sapropterin dihydrochloride) prescribing information. BioMarin Pharmaceutical Inc.
Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Biomarin Pharm	KUVAN	sapropterin dihydrochloride	FOR SOLUTION;ORAL	205065-001	Dec 19, 2013	AB	RX	Yes	Yes	9,216,178*PED	⤷ Start Trial			Y		⤷ Start Trial
Biomarin Pharm	KUVAN	sapropterin dihydrochloride	FOR SOLUTION;ORAL	205065-002	Oct 27, 2015	AB	RX	Yes	Yes	9,216,178*PED	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Details for Patent: 9,216,178

Which drugs does patent 9,216,178 protect, and when does it expire?

Summary for Patent: 9,216,178